Entrada Therapeutics is rated Buy with a fair value of $8.50, implying about 52% upside from the current $5.61 price. The company’s Duchenne muscular dystrophy drug ENTR-601-44 showed a disappointing initial increase in dystrophin, but this is attributed to lower pediatric drug exposure. Higher dosing results, expected in Q1 2027, could validate the company’s EEV platform and drive value. The valuation balances risk-adjusted pipeline prospects and strong cash reserves, with downside risk if higher dosing fails to improve outcomes. Key investment factors include whether increased drug exposure raises dystrophin levels significantly and maintains safety, with platform validation as a critical catalyst.
Entrada Therapeutics is the subject of this news, with Pluang market data providing context. As of Oct 10, 2026 11:02 WIB, 109 of 128 priced Health-sector US stocks on Pluang rose while 18 fell. Notable movers include Moderna (MRNA) at USD 225.00 with a 14.21% increase, Heron Therapeutics (HRTX) at USD 0.41 up 13.37%, and Humana (HUM) at USD 431.03 rising 11.34%.
At Malaysia's IGEM 2026, Sigenergy showcased its latest AI-driven energy technologies, including smart storage and inverter systems, highlighting its role in advancing sustainable energy. The company also signed MOUs with local partners Milieu and YT...
Ten-year U.S. Treasury yields reached 5.36% intraday, reflecting growing systemic sovereign debt issues. Despite these concerns, the stock market showed strength with the S&P 500 rising 1.2% and the Dow gaining 0.9%, supported by a 43-week expansion ...
Pump.fun's daily revenue, which funds half of its token buyback and burn program, fell 16% from $1.89 million on October 5 to $1.59 million on October 9, causing the token price to drop 16.8% from its weekly high. The buyback program, running until A...
Alphamin Resources Corp. operates two profitable tin mines in the Democratic Republic of Congo and is focusing on exploration around its Bisie resource, offering speculative growth potential. The company's current operations are stable and profitable...
A vote on Cardano proposes reducing the fixed minimum stake pool fee from 170 ADA to 75 ADA to help small pools remain viable amid declining block rewards. As of October 10, 2026, approval stands at 34.45% against a required 67%, with the vote closin...
